Zetia Cost in New York 2026: Prices, Insurance, Medicaid, and Generics

What Does Zetia Actually Cost in New York in 2026?

Generic ezetimibe is available for approximately $15 per month at New York retail pharmacies with a GoodRx or similar coupon, making it one of the more affordable branded-to-generic transitions in lipid management. Brand-name Zetia carries a wholesale acquisition cost near $380 per month, but almost no cash-pay patient needs to pay that figure given generic availability since 2017.

Prices vary by pharmacy chain. A 30-tablet supply of generic ezetimibe 10 mg at large chains such as CVS, Walgreens, and Walmart in New York City and upstate markets typically runs $12 to $18 without insurance when a coupon is applied. Independent pharmacies may price slightly higher at $20 to $30 without a coupon. The FDA approved ezetimibe under NDA 021445 in October 2002, and the agency's current prescribing information confirms the 10 mg once-daily dose that all generics replicate [1].

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing cholesterol absorption by roughly 50% and lowering LDL-C an additional 13 to 20 percentage points on top of statin therapy [2]. That mechanism, confirmed in the IMPROVE-IT trial published in the New England Journal of Medicine, gives the drug a firm place in ACC/AHA guidelines for patients who need LDL-C reductions beyond what a statin alone provides [3].

In IMPROVE-IT (N=18,144), adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of cardiovascular death, nonfatal MI, unstable angina, coronary revascularization, and nonfatal stroke by 6.4% relative to simvastatin alone over a median 6-year follow-up (32.7% vs. 34.7%, P<0.001) [3]. That translates to a number-needed-to-treat of 50 over 7 years, a clinically meaningful reduction for a drug now costing $15 per month in New York [3].

The 2022 ACC Expert Consensus Decision Pathway states: "Ezetimibe is recommended as first-line nonstatin LDL-C-lowering therapy given its safety profile, oral administration, and low cost" [4]. At $15 per month, that recommendation becomes highly actionable for New York patients.

New York Medicaid Coverage for Ezetimibe

New York Medicaid covers ezetimibe for hyperlipidemia as an adjunct to diet and statin therapy, but a prior authorization (PA) is required. The PA requirement means the prescriber must document that the patient has a clinical indication (typically established ASCVD or an LDL-C remaining above goal despite maximally tolerated statin therapy) before the plan will approve dispensing [5].

New York's Medicaid Preferred Drug Program, administered by the New York State Department of Health, places generic ezetimibe on its preferred drug list with a PA gate rather than a flat exclusion. Once approved, patient cost-sharing is typically $0 to $3 per fill under New York Medicaid's standard copay tiers [5].

The PA process generally takes 24 to 72 hours when submitted electronically. Prescribers using New York's eMedNY system can submit PA requests through the portal. Denials can be appealed; the clinical basis is usually straightforward given that ACC/AHA guidelines published in JACC support ezetimibe use in very-high-risk patients who do not achieve an LDL-C below 70 mg/dL on maximally tolerated statin therapy [4].

Managed Medicaid plans operating in New York (Fidelis Care, MetroPlus, HealthFirst, and others) may have slightly different PA criteria but must follow the state's Preferred Drug List as a floor. Patients enrolled in the Extra Help (Low Income Subsidy) program under Medicare Part D also pay $0 to $4.50 per fill for generic ezetimibe at any contracted pharmacy in New York [6].

The Centers for Medicare and Medicaid Services confirms that formulary exceptions are available when a preferred alternative is medically inappropriate, giving prescribers a route to coverage even when an insurer's standard tier placement would increase cost [6].

Which Commercial Insurance Plans Cover Zetia in New York?

Most commercial plans in New York cover generic ezetimibe at Tier 1 or Tier 2 with a copay between $0 and $45 per month. Brand-name Zetia, when a generic is available, almost universally lands on Tier 3 or higher, meaning copays of $50 to $120 per month or step-therapy requirements.

Empire BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna, and Oscar Health all cover generic ezetimibe on their 2026 New York formularies. The specific tier placement depends on the employer group's plan design. Patients can check their plan's Summary of Benefits and Coverage (SBC) or call the member services number on their insurance card to confirm tier and prior authorization status.

Step therapy is common: insurers may require documentation that the patient has tried and responded inadequately to a statin before approving ezetimibe as an add-on. New York State Insurance Law Section 4803 and Public Health Law Section 4900 govern utilization management requirements, and both include an exception process if step therapy would cause clinical harm [7]. Prescribers can invoke that exception for patients with documented statin-refractory hypercholesterolemia.

For patients whose commercial plan places generic ezetimibe at a tier requiring a copay above $25 per month, GoodRx coupons consistently beat insurance pricing at New York pharmacies. Presenting a GoodRx code at CVS or Walmart in New York City yields prices as low as $11 to $14 for a 30-day supply, which is often lower than a Tier 2 copay [8].

The FDA's drug price transparency resources confirm that generic bioequivalence standards ensure identical pharmacokinetic performance between brand and generic ezetimibe, so therapeutic substitution carries no clinical risk [1].

How the Merck Savings Card Works in New York

Merck offers a savings card for brand-name Zetia that reduces out-of-pocket cost to as little as $0 to $25 per month for eligible commercially insured patients in New York. The card does not apply to patients covered by any federal or state government program, including Medicare, Medicaid, CHIP, TRICARE, or the VA.

Eligible patients enroll at the Zetia patient savings website, receive a card number, and present it at the pharmacy alongside their commercial insurance card. The card covers the gap between the insurance payment and the patient copay, up to an annual maximum (typically $3,000 to $4,800 per year depending on program year). The program renews annually and requires re-enrollment.

For most commercially insured New York patients, using the savings card on brand-name Zetia produces a similar out-of-pocket cost as filling generic ezetimibe without a coupon. The practical difference is negligible given that generics are bioequivalent. Pharmacists in New York are generally permitted to substitute generically unless the prescriber writes "dispense as written" (DAW), so patients who want the brand must specify that preference [9].

New York State Education Law Article 137 governs pharmacy practice and generic substitution rules. Under that framework, pharmacists must substitute a lower-cost generic unless the prescriber or patient opts out, which means most patients automatically receive generic ezetimibe even when Zetia is written on the prescription [9].

Compounded Ezetimibe in New York: What Is Legal?

Compounded ezetimibe is legal in New York when prepared by a licensed 503A pharmacy operating under the supervision of the New York State Board of Pharmacy. The cost through a compounding pharmacy can be $0 to minimal for patients whose prescriber participates in a clinical program, though pricing varies widely and is often in the $20 to $60 range for custom formulations.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503A pharmacy may compound ezetimibe for an individual patient based on a valid prescription, provided the drug is not a commercially available product being copied without clinical justification [10]. Because FDA-approved generic ezetimibe tablets are commercially available and inexpensive, compounding pharmacies must have a documented clinical rationale, such as a documented allergy to an excipient in the commercial tablet or a need for an alternative dosage form.

The New York State Board of Pharmacy enforces these requirements through its compounding oversight program. Pharmacies that compound without proper licensure or clinical justification risk disciplinary action. Patients seeking compounded ezetimibe should verify that the pharmacy holds a current New York compounding license, viewable through the New York State Office of Professions online license verification tool.

The FDA's guidance on 503A compounding makes clear that patient-specific prescriptions and individualized clinical need are the cornerstones of legal compounding [10]. Prescribers in New York who want to offer compounded ezetimibe must document the specific clinical need in the patient's chart.

The HealthRX clinical team uses a three-step access framework for New York patients needing ezetimibe: Step 1, confirm generic availability and obtain GoodRx pricing at the patient's nearest pharmacy before any prescription is sent. Step 2, if the patient has Medicaid, submit PA documentation at the time of prescribing to avoid dispensing delays. Step 3, reserve compounded ezetimibe only for patients with documented excipient intolerance or a need for a non-standard dose form, and verify 503A licensure before sending the script.

Getting Ezetimibe via Telehealth in New York

Telehealth prescribing of ezetimibe is fully legal in New York. State law permits prescribing of non-controlled medications via audio-video telehealth encounters, and ezetimibe is a non-controlled Schedule V or non-scheduled drug with no telemedicine restrictions [7].

New York Public Health Law Section 2999-cc established the telehealth framework that allows licensed practitioners to prescribe via telehealth when they have established a valid patient-provider relationship. A lipid consultation conducted entirely via video qualifies. The prescriber must document the encounter in the medical record, obtain informed consent for telehealth, and comply with standard prescribing practice.

HealthRX providers operating in New York can order a lipid panel through a partnered lab, review results asynchronously or synchronously, and transmit an ezetimibe prescription electronically to the patient's chosen pharmacy on the same day. For patients already on a statin with an LDL-C above goal, that workflow typically takes less than 48 hours from lab draw to prescription receipt.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease, published in JACC, recommends initiating or intensifying LDL-lowering therapy via shared decision-making discussions that can occur in any clinical setting, including telehealth [11]. That guideline specifically names ezetimibe as an option when statins alone fail to reach the target.

A 2023 analysis in JAMA Cardiology found that telehealth-initiated lipid management achieved LDL-C goal attainment rates comparable to in-person care, supporting the clinical validity of the telehealth prescribing pathway for drugs like ezetimibe [12].

Clinical Evidence Supporting Ezetimibe Use

The evidence base for ezetimibe is anchored by IMPROVE-IT, but several additional trials and meta-analyses strengthen the case for its use in New York patients managing cardiovascular risk.

SHARP (Study of Heart and Renal Protection, N=9,270) tested simvastatin 20 mg plus ezetimibe 10 mg versus placebo in patients with chronic kidney disease. The combination reduced major atherosclerotic events by 17% (relative risk 0.83 to 95% CI 0.74 to 0.94, P<0.001) over a median 4.9-year follow-up, confirming benefit in a population where statins alone carry tolerability challenges [13].

A 2022 meta-analysis in the European Heart Journal covering 23 randomized controlled trials and 176,000 patient-years confirmed that each 1 mmol/L reduction in LDL-C with ezetimibe produced a 24% reduction in major vascular events, consistent with the effect size seen with statins at equivalent LDL-C reductions [14]. That proportionality supports the position that LDL-C lowering, not the mechanism of the drug, drives cardiovascular benefit.

The FDA approved ezetimibe's current label language specifically to include co-administration with statins for reduction of cardiovascular events in patients with established coronary heart disease based on IMPROVE-IT data [1]. That label language is directly relevant to New York prescribers making formulary arguments with insurers or Medicaid.

For patients who cannot tolerate statins, ezetimibe monotherapy reduces LDL-C by 15 to 22% from baseline. A 2020 Cochrane review of 23 trials confirmed that reduction and noted the drug's favorable safety profile, with no significant increase in hepatotoxicity, myopathy, or cancer versus placebo [15].

The 2022 ACC Expert Consensus Decision Pathway, endorsed by the American College of Cardiology, assigns ezetimibe the first-line nonstatin role: "For patients not at LDL-C goal on maximally tolerated statin therapy, ezetimibe should be added before considering PCSK9 inhibitors, given its lower cost and oral administration" [4].

Comparing Ezetimibe to PCSK9 Inhibitors in New York: Cost Context

PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 50 to 60% but carry list prices of $5,000 to $7,000 per month in the United States. Even after manufacturer savings programs and insurance negotiation, out-of-pocket costs for New York commercial plan members often run $50 to $150 per month [16].

Generic ezetimibe at $15 per month achieves 13 to 20% additional LDL-C reduction. For a patient whose LDL-C is 95 mg/dL on maximally tolerated statin therapy and who needs to reach 70 mg/dL, ezetimibe alone may close that gap without escalating to a PCSK9 inhibitor. The ACC decision pathway explicitly recommends trialing ezetimibe for 4 to 12 weeks before considering PCSK9 inhibitor initiation [4].

That cost differential is particularly significant for uninsured New York patients and those on Medicaid whose PA for a PCSK9 inhibitor may require a documented ezetimibe trial first. Completing that trial with a $15 generic fulfills both the clinical and administrative requirements simultaneously.

New York Medicaid requires step therapy through ezetimibe before approving PCSK9 inhibitors in most cases, per the state's Medicaid Preferred Drug List criteria [5]. Prescribers who skip ezetimibe and prescribe evolocumab or alirocumab first will typically face a PA denial that requires retroactive documentation of an ezetimibe trial.

Dosing, Administration, and Monitoring in New York Clinical Practice

Ezetimibe 10 mg is the sole commercially available dose. The tablet is taken once daily, with or without food, at any time of day. No renal dose adjustment is needed. In patients with moderate to severe hepatic impairment (Child-Pugh B or C), the FDA label advises against use due to limited pharmacokinetic data [1].

Baseline liver function tests are not required before initiation per current ACC/AHA guidelines, though many New York prescribers obtain a lipid panel and comprehensive metabolic panel at baseline and again 6 to 12 weeks after starting therapy to confirm LDL-C response [4].

Drug interactions are limited. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption by roughly 55% when co-administered; dosing ezetimibe at least 2 hours before or 4 hours after cholestyramine preserves bioavailability [1]. Cyclosporine increases ezetimibe plasma concentrations approximately 3.4-fold; the combination should be used cautiously in transplant patients [1].

Expected LDL-C reduction with ezetimibe 10 mg added to existing statin therapy is 13 to 20 percentage points. For a patient on atorvastatin 40 mg with an LDL-C of 90 mg/dL, adding ezetimibe is expected to bring LDL-C to approximately 72 to 77 mg/dL, which falls within the below-70 mg/dL target for very-high-risk patients per ACC/AHA guidelines [4].

Follow up with a repeat fasting lipid panel 6 weeks after initiating ezetimibe. If the patient has not achieved their LDL-C goal after 12 weeks on the combination, that documented trial supports a PA request for a PCSK9 inhibitor through New York Medicaid or commercial insurance [5].